Skip to main content
TipRanks
Go Ultimate75% OFF

Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis

0 Followers
IN:BALAXI

Balaxi Pharmaceuticals Limited

(NSE:BALAXI)

Select Model
Rating:57Neutral
Price Target:INR 27.00â–¼(-14.69% Downside)
Action:reiterated
Date:11/18/26

Financial performance is the largest factor with a moderate score due to cash flow challenges and revenue inconsistency, while positive technical analysis boosts the score; valuation remains a drag with elevated P/E.

Positive Factors
Moderate LeverageManageable leverage and a sizable equity base provide Balaxi with greater financial flexibility than a highly indebted business. This balance-sheet position can help support ongoing operations and measured expansion while reducing the burden of debt service on future cash flows.
Negative Factors
Persistent Cash BurnRecurring negative operating and free cash flow shows that reported earnings are not converting into liquidity. If this pattern persists, Balaxi may face greater funding pressure, reduced flexibility for investment, and a higher need to rely on external financing.

Balaxi Pharmaceuticals Limited (BALAXI) vs. iShares MSCI India ETF (INDA)

-60%-50%-40%-30%-20%-10%0%10%IN:BALAXI-15.24%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 2.01B
Dividend Yield
―
Average Volume (3M)
68.31K
Price to Earnings (P/E)
51.0
Beta (1Y)
1.05
Revenue Growth
―
EPS Growth
―
Country
India
Employees
500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Balaxi Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated...

Balaxi Pharmaceuticals Limited Financial Statement Overview

Summary

Volatile revenue and negative recent cash flows offset by solid balance sheet growth and margin expansion.

Income Statement

45Neutral

Balance Sheet

75Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.73B2.73B2.89B2.41B3.36B2.79B
Gross Profit1.20B1.14B1.27B1.13B1.34B837.91M
EBITDA103.60M74.45M305.64M456.59M603.82M560.20M
Net Income14.17M14.17M250.70M-23.87M459.63M476.58M
Balance Sheet
Total Assets3.37B3.37B3.10B2.58B2.40B1.76B
Cash, Cash Equivalents and Short-Term Investments145.59M145.59M394.00M622.91M282.17M71.93M
Total Debt576.49M576.49M534.25M194.04M133.06M36.38M
Total Liabilities879.53M879.53M786.06M569.79M567.89M633.07M
Stockholders Equity2.49B2.49B2.32B2.01B1.83B1.13B
Cash Flow
Free Cash Flow25.78M-451.69M-589.01M32.97M-89.05M68.00M
Operating Cash Flow149.66M-82.44M-377.82M48.66M60.75M341.44M
Investing Cash Flow-167.16M-207.79M-217.64M-10.46M-105.65M-284.48M
Financing Cash Flow11.99M41.82M366.55M302.54M255.13M-1.63M

Balaxi Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price31.65

Price Trends

50DMA22.52Positive
100DMA23.16Positive
200DMA23.12Positive

Market Momentum

MACD1.21Negative
RSI80.29Negative
STOCH80.84Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Positive. The current price of 31.65 is above the 20-day moving average (MA) of 21.96, above the 50-day MA of 22.52, and above the 200-day MA of 23.12, indicating a bullish trend. The MACD of 1.21 indicates Negative momentum. The RSI at 80.29 is Negative, neither overbought nor oversold. The STOCH value of 80.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BALAXI.

Balaxi Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:BALAXI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.39B10.73――9.40%34.12%
IN:ALPAIN:ALPA60NeutralINR 1.09B30.71――0.46%-83.31%
IN:BALAXIIN:BALAXI57NeutralINR 1.75B51.05――――
IN:BALPHARMAIN:BALPHARMA53NeutralINR 1.40B17.27―1.41%18.79%-2.58%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:NATCAPSUQIN:NATCAPSUQ38UnderperformINR 1.51B-6.24――8.84%-285.42%

* Healthcare Sector Average

Performance Comparison

-50%0%50%IN:BALAXIIN:ALPAIN:BALPHARMAIN:PARIN:NATCAPSUQIN:BIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:BALAXI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:BALAXIBalaxi Pharmaceuticals Limited31.65-4.33-12.03%
IN:ALPAAlpa Laboratories Limited51.93-27.97-35.01%
IN:BALPHARMABal Pharma Limited84.608.0210.47%
IN:PARPar Drugs and Chemicals Limited113.3620.7122.35%
IN:NATCAPSUQNatural Capsules Limited138.10-42.40-23.49%
IN:BIBilcare Ltd84.202.553.12%

Balaxi Pharmaceuticals Limited Corporate Events

Balaxi Pharma Reports Nil Physical Share Transfer Re-Lodgement Requests for September 2026

Oct 6, 2026

Balaxi Pharmaceuticals Limited has submitted a registrar and transfer agent report to the National Stock Exchange of India on the status of re-lodgement requests for transfer of physical shares, as mandated by a SEBI circular issued in January 2026....

Balaxi Pharmaceuticals Closes Trading Window Ahead of September 2026 Results

Sep 27, 2026

Balaxi Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code o...

Balaxi Pharma Shareholders Clear Second Term for Independent Director Akshita Ostwal

Aug 24, 2026

Balaxi Pharmaceuticals Limited has announced that its shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director at the company’s 83rd Annual General Meeting held on 24 August 2026. Her second term on the board will run...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026